Curious about today's AI digest?ai-tldr.dev
Pomegra LogoPomegra

Daily Digest

BriefMarket · mixedLow impact
Esc

Ionis Stock Falls 5% as Zanvastro Wins First FDA Nod for Alexander Disease

Ionis Pharmaceuticals IR2 min read8 sources

Why did Ionis Pharmaceuticals stock fall on FDA approval day?

Ionis Pharmaceuticals (IONS) stock fell 5.2% to roughly $58 on Thursday, September 3, after the FDA approved Zanvastro for Alexander disease while partner Novartis' pelacarsen cardiovascular trial failed.

Key numbers

FDA Approval DateSeptember 3, 202619 days ahead of PDUFA deadline
Gait Speed Endpoint33.3% LSM difference vs. control at Week 61p=0.041; control group lost 33% of gait speed
Annual List Price$1.14M/year ($285,000 per dose) (per [3])4 doses per year, intrathecal injection
U.S. Patient Population~300~1 in 1–3 million people worldwide
Recordati Ex-U.S. License$30M upfront + royaltiesEurope and Japan submissions planned 2027
Peak Sales Estimate (William Blair)$160M by 2040 (per [3]) — conflicts with $295M per [5]Primary document omits guidance; analyst estimates vary

What happened

Ionis Pharmaceuticals (IONS) stock fell 5.2% to roughly $58 on Thursday, September 3, after the FDA approved Zanvastro for Alexander disease while partner Novartis' pelacarsen cardiovascular trial failed. The approval came 19 days ahead of its September 22 PDUFA deadline, making Zanvastro the first-ever disease-modifying therapy for Alexander disease, a progressive neurological condition affecting roughly 300 Americans. In the pivotal trial of 49 patients, Zanvastro stabilized walking speed over 61 weeks while untreated patients lost 33% of theirs — a statistically significant difference (p=0.041). Priced at $285,000 per dose or $1.14 million per year (per), the drug is Ionis' first independent neurology launch; the company licensed ex-U.S. rights to Italy-based Recordati for $30 million upfront in June 2026.

Why it matters

Zanvastro is the first treatment that can change the course of Alexander disease — a condition so rare and so severe that many affected children lose their ability to walk with no alternative other than symptom management. For Ionis Pharmaceuticals the approval is a strategic turning point: the company is now selling a neurology drug on its own for the first time, without a large-pharma partner. Alongside the approval the FDA awarded Ionis a rare pediatric disease priority review voucher, which can be sold on the open market for an estimated $100 million or more or used to accelerate a future Ionis pipeline drug through review.

Who this affects

Marketmixed
Low impact
Rare-disease biotech stocks gain modestly on historic first approval.
Companybullish
Medium impact
Ionis gains neurology independence and a potentially valuable PRV asset.
Competitorsneutral
Low impact
Alnylam and Sarepta face no direct competitive threat from Zanvastro.
Industrybullish
Low impact
Antisense oligonucleotide therapy proven viable in ultra-rare pediatric neurology.

Ionis Pharmaceuticals vs Alnylam Pharmaceuticals, Sarepta Therapeutics

Ionis PharmaceuticalsIONS:NASDAQ$7.46B+1.0%$874Mn/a
Alnylam PharmaceuticalsALNY:NASDAQ$32.69B+2.0%$4.80B31.9×
Sarepta TherapeuticsSRPT:NASDAQ$2.13B—$1.97B36.4×

As of 2026-09-22

How we got here

  1. FDA accepts zilganersen NDA for priority review; PDUFA set for Sept 22, 2026

  2. Ionis licenses ex-U.S. zilganersen rights to Recordati for $30M upfront

  3. FDA approves Zanvastro — first-ever disease-modifying therapy for Alexander disease

  4. Partner Novartis' pelacarsen heart trial fails Phase 3; IONS falls ~12%

  5. Original PDUFA date reached; Zanvastro commercial availability confirmed in U.S.

What to watch

  • Zanvastro U.S. uptake — first commercial quarter tests $1.14M/year pricing acceptanceQ4 2026
  • PRV sale or internal-use decision by Ionis management; potential $100M+ cash eventQ4 2026
  • Q3 2026 earnings call — first Zanvastro revenue disclosure and updated full-year outlook2026-10-28

Educational content only. Not investment advice.

More briefsAll briefs →